论文部分内容阅读
目的 :探讨转化生长因子 β1(TGF - βl)和干扰素γ(IFN -γ)在肝硬化、肝癌中的表达及临床意义。方法 :采用酶联免疫吸附试验法 (ELISA)测定了 4 8例肝硬化、4 0例原发性肝癌、6例转移性肝癌及 2 0例正常对照者血清中TGF - β1和IFN -γ含量。结果 :原发性肝癌患者血清TGF - β1水平显著高于肝硬化组和正常对照组 ,血清IFN -γ水平明显低于肝硬化组和正常对照组 (P均 <0 .0 5 )。原发性肝癌组的血清TGF - β1水平显著高于转移性肝癌组 (P <0 .0 5 ) ,而两组IFN -γ水平无显著性差异 (P >0 .0 5 )。肝硬化及转移性肝癌患者血清TGF - β1和IFN -γ水平无显著性差异 (P均 >0 .0 5 )。肿块数目≥ 3个 ,直径≥ 3cm和AFP≤ 2 0ng/ml的原发性肝癌患者血清TGF - β1水平明显增高 ,血清IFN -γ水平显著降低 (P均 <0 .0 5 )。 2 0例原发性肝癌患者经介入或手术治疗后血清TGF - β1水平明显下降 ,IFN -γ水平明显上升 (P <0 .0 5 )。结论 :血清TGF - β1和IFN -γ可作为新的血清学标志应用于原发性肝癌的鉴别诊断和近期疗效的判断。
Objective: To investigate the expression of transforming growth factor β1 (TGF - β1) and interferon γ (IFN - γ) in cirrhosis and hepatocellular carcinoma and its clinical significance. Methods: Serum levels of TGF - β1 and IFN - γ in 48 cases of liver cirrhosis, 40 cases of primary hepatocellular carcinoma, 6 cases of metastatic liver cancer and 20 cases of normal controls were measured by enzyme - linked immunosorbent assay (ELISA) . Results: The serum levels of TGF - β1 in patients with primary liver cancer were significantly higher than those in patients with cirrhosis and normal controls. The levels of serum IFN - γ in patients with primary liver cancer were significantly lower than those in patients with cirrhosis and normal controls (all P <0.05). The level of serum TGF - β1 in patients with primary liver cancer was significantly higher than that in patients with metastatic liver cancer (P <0.05), while there was no significant difference in the level of IFN - γ between the two groups (P> 0.05). Serum levels of TGF - β1 and IFN - γ in patients with cirrhosis and metastatic liver cancer showed no significant difference (all P> 0.05). The serum levels of TGF - β1 and the levels of serum IFN - γ in patients with primary hepatic carcinoma ≥ 3 cm and AFP ≤ 20 ng / ml were significantly decreased (all P <0.05). Serum levels of TGF - β1 were significantly decreased and IFN - γ levels were significantly increased in 20 patients with primary liver cancer after intervention or surgery (P <0.05). Conclusion: Serum TGF - β1 and IFN - γ can be used as new serological markers in the differential diagnosis and short - term curative effect of primary liver cancer.